Inhibition of translation initiation as a novel therapeutic strategy against MYCN-amplified neuroblastoma |
Dana-Farber Cancer Institute / Rani George, MD, PhD |
Innovation Grants |
2022 |
Massachusetts |
Targeting mechanisms of Siglec15-mediated immune evasion in hematologic malignancies |
Emory University / Christopher Porter, MD |
Innovation Grants |
2019 |
Georgia |
Identifying Mechanisms of Glucocorticoid Resistance in Pediatric Acute Lymphoblastic |
University of Massachusetts Medical School / Michelle Kelliher, PhD |
Innovation Grants |
2015 |
Massachusetts |
Targeting Pediatric Brain Tumors Using PTPmu Nanochains with Radiofrequency-Releasable Therapeutics |
Case Western Reserve University / Susann Brady-Kalnay, PhD & Efstathios Karathanasis, PhD |
Innovation Grants |
2017 |
Ohio |
A novel mouse model of rhabdomyosarcoma |
Vanderbilt University Medical Center / Chin Chiang, PhD |
Innovation Grants |
2012 |
Tennessee |
Characterization of Novel OTX2-semaphorin Gene Signaling Pathways Regulating the ‘Grow and Go’ Arms of Highly Aggressive Medulloblastomas |
University of Manitoba / Tamra Werbowetski-Ogilvie, PhD |
Innovation Grants |
2017 |
Manitoba |
Molecular diagnostic, prognostic, and therapeutic approaches toward Ewing sarcoma.
|
Huntsman Cancer Institute / Stephen Lessnick |
Innovation Grants |
2009 |
Utah |
Epigenetic Enhancement of MHCI to Augment Neuroblastoma Immunotherapy |
University of Wisconsin - Madison / Paul Sondel, MD, PhD and Amy Erbe-Gurel, PhD |
Innovation Grants |
2022 |
Wisconsin |
Two-pronged Cell Therapy: Engineering T Cells to Redirect Bystander T- and NK-Cells to Pediatric Cancer |
Baylor College of Medicine / Stephen Gottschalk, M.D. |
Innovation Grants |
2014 |
Texas |